<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368328</url>
  </required_header>
  <id_info>
    <org_study_id>DM2</org_study_id>
    <nct_id>NCT01368328</nct_id>
  </id_info>
  <brief_title>Effect of the Chromium Nicotinate on Type 2 Diabetes</brief_title>
  <official_title>Effect of Chromium Supplementation on Insulin Sensitivity in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Goias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal de Goias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of micronutrients in diabetes is not well understood. Studies have demonstrated the
      relationship between low chromium serum levels and insulin resistance. This study aims to
      evaluate the effect of chromium nicotinate on increasing insulin sensitivity in patients with
      type 2 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin is a hormone secreted by cells β of pancreatic islets in response to increased levels
      of glucose and serum amino acids. Insulin resistance means a decrease in the ability of
      insulin to stimulate glucose utilization because is disabled in the insulin receptor,
      decrease in concentration of receptors or failure mechanism of cell transit. Recently, the
      discovery of a substance called low molecular weight chromium-binding substance (LMWCr),
      showed the ability of this substance in amplifying insulin signaling, increasing the
      sensitivity of insulin receptors in the plasma membrane. This way, the capacity of LMWCr in
      activating the insulin receptor depends on levels of serum chromium. Thus, the hypothesis
      that the nutritional status of individual poor chromium contributes to the decrease in
      glucose tolerance and consequently, for type 2 Diabetes. Thus, it becomes necessary to assess
      the effect of supplementation of chromium in increased insulin sensitivity in patients with
      type 2 Diabetes. This is a double-blind randomized clinical trial, consisting of a period of
      three months of nutritional intervention with chromium nicotinate, biochemical and
      anthropometric evaluation and assessment of food profile and physical activity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity as assessed with homeostatic model assessment (HOMA)</measure>
    <time_frame>baseline, 45 days and 90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting triglycerides, high density lipoprotein cholesterol, low density lipoprotein cholesterol</measure>
    <time_frame>baseline, 45 days and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>baseline, 45 days, 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body fat accessed with bioimpedance</measure>
    <time_frame>baseline, 45 days, 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist circumference</measure>
    <time_frame>baseline, 45 days, 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urea and creatinine</measure>
    <time_frame>baseline, 45 days, 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chromium nicotinate 50 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chromium nicotinate 200 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chromium nicotinate</intervention_name>
    <description>The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Chromium nicotinate 50 mcg</arm_group_label>
    <arm_group_label>Chromium nicotinate 200 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  Body mass index &gt; 25 kg/m2

          -  Increased waist circumference

        Exclusion Criteria:

          -  Subjects on insulin

          -  Pregnancy

          -  Patients with chronic complications as heart disease, nephropathy, retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marília Mendonça Guimarães</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Nutrição - Universidade Federal de Goiás</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Sebastiana Silva</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Educação Física - Universidade Federal de Goiás</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Goiania Municipal Health Departament</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74000000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.diabetes.org/</url>
    <description>American Diabetes Association</description>
  </link>
  <reference>
    <citation>Anderson RA. Chromium and insulin resistance. Nutr Res Rev. 2003 Dec;16(2):267-75. doi: 10.1079/NRR200366.</citation>
    <PMID>19087394</PMID>
  </reference>
  <reference>
    <citation>Kleefstra N, Houweling ST, Bakker SJ, Verhoeven S, Gans RO, Meyboom-de Jong B, Bilo HJ. Chromium treatment has no effect in patients with type 2 diabetes in a Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2007 May;30(5):1092-6. Epub 2007 Feb 15.</citation>
    <PMID>17303791</PMID>
  </reference>
  <reference>
    <citation>Kleefstra N, Houweling ST, Jansman FG, Groenier KH, Gans RO, Meyboom-de Jong B, Bakker SJ, Bilo HJ. Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. Diabetes Care. 2006 Mar;29(3):521-5.</citation>
    <PMID>16505499</PMID>
  </reference>
  <reference>
    <citation>Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, Cefalu WT. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care. 2006 Aug;29(8):1826-32.</citation>
    <PMID>16873787</PMID>
  </reference>
  <reference>
    <citation>Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, Chowdhury S. Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem. 2002 Nov;13(11):690-697.</citation>
    <PMID>12550067</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>June 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2011</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marília Mendonça Guimarães</name_title>
    <organization>Faculdade de Nutrição Universidade Federal de Goiás</organization>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Chromium</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chromium</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

